Display options
Cite
Skvortsova EV, Sinenko SA, Tomilin AN. Immortalized murine fibroblast cell lines are refractory to reprogramming to pluripotent state. Oncotarget. 2018;9(81):35241-35250doi: 10.18632/oncotarget.26235.
Skvortsova, E. V., Sinenko, S. A., & Tomilin, A. N. (2018). Immortalized murine fibroblast cell lines are refractory to reprogramming to pluripotent state. Oncotarget, 9(81), 35241-35250. https://doi.org/10.18632/oncotarget.26235
Skvortsova, Elena V, et al. "Immortalized murine fibroblast cell lines are refractory to reprogramming to pluripotent state." Oncotarget vol. 9,81 (2018): 35241-35250. doi: https://doi.org/10.18632/oncotarget.26235
Skvortsova EV, Sinenko SA, Tomilin AN. Immortalized murine fibroblast cell lines are refractory to reprogramming to pluripotent state. Oncotarget. 2018 Oct 16;9(81):35241-35250. doi: 10.18632/oncotarget.26235. eCollection 2018 Oct 16. PMID: 30443291; PMCID: PMC6219659.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2018 Oct 16;9(81):35241-35250. doi: 10.18632/oncotarget.26235. eCollection 2018 Oct 16.

Immortalized murine fibroblast cell lines are refractory to reprogramming to pluripotent state.

Oncotarget

Elena V Skvortsova, Sergey A Sinenko, Alexey N Tomilin

Affiliations

  1. Institute of Cytology, Russian Academy of Sciences, St Petersburg, Russian Federation.
  2. Division of Molecular and Radiation Biophysics, B.P. Konstantinov Petersburg Nuclear Physics Institute, NRC "Kurchatov Institute", Orlova Roscha, Gatchina, Russian Federation.
  3. St Petersburg State University, St Petersburg, Russian Federation.

PMID: 30443291 PMCID: PMC6219659 DOI: 10.18632/oncotarget.26235

Abstract

To date different cell types of various mammalian species have been reprogrammed to induced pluripotent stem cells (iPSCs) using Yamanaka's cocktail of transcription factors (Oct4, Klf4, Sox2, and cMyc). It has been shown that several primary human cancer cell lines could be reprogrammed to iPSCs. We sought if immortalized mouse fibroblast cell lines could also be reprogrammed to iPSCs. The approach of generating iPSCs from such cells should be valuable in different experimental settings as it allows clonally derive cell lines carrying mutations whose impact on reprogramming could be next evaluated. Therefore, we investigated reprogramming of widely used immortalized cell lines (NIH3T and STO), as well as of

Keywords: NIH3T3; STO; cell reprogramming; iPSC; pluripotency

Conflict of interest statement

CONFLICTS OF INTEREST None.

References

  1. Nature. 2009 Aug 27;460(7259):1132-5 - PubMed
  2. Oncotarget. 2015 Sep 15;6(27):23204-12 - PubMed
  3. Stem Cell Reports. 2017 Nov 14;9(5):1721-1734 - PubMed
  4. Stem Cells Dev. 2011 May;20(5):795-807 - PubMed
  5. Cancer Sci. 2012 Mar;103(3):393-9 - PubMed
  6. PLoS One. 2011;6(11):e27345 - PubMed
  7. Cancer Biother Radiopharm. 2012 Dec;27(10):694-700 - PubMed
  8. Curr Biol. 2008 Jun 24;18(12):890-4 - PubMed
  9. Stem Cell Reports. 2015 Sep 8;5(3):350-64 - PubMed
  10. Oncotarget. 2017 Jun 27;8(26):42700-42711 - PubMed
  11. Curr Biol. 2009 Nov 3;19(20):1718-23 - PubMed
  12. Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):157-62 - PubMed
  13. Nat Chem Biol. 2014 Aug;10(8):632-639 - PubMed
  14. Cell Res. 2011 Mar;21(3):486-501 - PubMed
  15. Turk J Haematol. 2018 May 21;35(4):260-264 - PubMed
  16. Oncotarget. 2017 Feb 7;8(6):10050-10063 - PubMed
  17. Nat Commun. 2012;3:1085 - PubMed
  18. Blood. 2009 May 28;113(22):5476-9 - PubMed
  19. J Genet Genomics. 2010 Jul;37(7):475-82 - PubMed
  20. Stem Cells. 2010 Oct;28(10):1728-40 - PubMed
  21. BMC Genomics. 2015;16 Suppl 13:S6 - PubMed
  22. Cell Cycle. 2011 Nov 1;10(21):3658-77 - PubMed
  23. Open Biol. 2017 Apr;7(4): - PubMed
  24. Cell. 2006 Aug 25;126(4):663-76 - PubMed
  25. Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):40-5 - PubMed
  26. Sci Rep. 2017 Dec 22;7(1):18094 - PubMed
  27. J Cancer. 2016 Nov 25;7(15):2296-2303 - PubMed
  28. PLoS Biol. 2008 Oct 21;6(10):e253 - PubMed
  29. Nature. 2009 Aug 27;460(7259):1145-8 - PubMed
  30. Mol Reprod Dev. 2010 Jan;77(1):2 - PubMed
  31. Cell Reprogram. 2015 Feb;17(1):7-18 - PubMed
  32. Epigenetics. 2014 Jun;9(6):798-802 - PubMed
  33. Oncol Lett. 2015 Jan;9(1):55-62 - PubMed
  34. Blood. 2012 Jun 28;119(26):6234-42 - PubMed
  35. Cell. 2008 Apr 18;133(2):250-64 - PubMed
  36. Genesis. 2007 Jul;45(7):456-9 - PubMed
  37. Cell Stem Cell. 2008 Mar 6;2(3):230-40 - PubMed
  38. Genes Dev. 2013 Mar 15;27(6):654-69 - PubMed
  39. J Virol. 2003 Aug;77(16):8957-61 - PubMed
  40. Nat Genet. 2009 Sep;41(9):968-76 - PubMed
  41. Cell Stem Cell. 2008 Nov 6;3(5):568-74 - PubMed
  42. PLoS One. 2010 Sep 17;5(9):null - PubMed
  43. Cell Cycle. 2012 Mar 1;11(5):974-89 - PubMed
  44. Stem Cells. 2009 Mar;27(3):543-9 - PubMed
  45. Science. 2008 Aug 1;321(5889):699-702 - PubMed
  46. Stem Cells. 2008 Oct;26(10):2467-74 - PubMed
  47. Acta Naturae. 2009 Jul;1(2):91-2 - PubMed
  48. Nature. 2009 Aug 27;460(7259):1140-4 - PubMed
  49. Atheroscler Suppl. 2018 Sep;35:e6-e13 - PubMed
  50. Blood. 2010 May 20;115(20):4039-42 - PubMed
  51. Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42 - PubMed
  52. J Cell Sci. 2009 Oct 1;122(Pt 19):3502-10 - PubMed
  53. Stem Cell Reports. 2016 Oct 11;7(4):602-618 - PubMed
  54. Int J Hematol. 2013 Aug;98(2):145-52 - PubMed
  55. J Histochem Cytochem. 2013 Apr;61(4):306-12 - PubMed
  56. Hum Mol Genet. 2012 May 1;21(9):2054-67 - PubMed
  57. Leukemia. 2016 Mar;30(3):674-82 - PubMed
  58. Cloning Stem Cells. 2006 Fall;8(3):174-88 - PubMed
  59. Cell Stem Cell. 2009 Jul 2;5(1):111-23 - PubMed
  60. Cytometry A. 2013 Jan;83(1):18-26 - PubMed
  61. Cell. 2012 Dec 21;151(7):1617-32 - PubMed
  62. J Biol Chem. 2009 Jun 26;284(26):17634-40 - PubMed
  63. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12759-64 - PubMed
  64. Nat Biotechnol. 2010 Aug;28(8):848-55 - PubMed
  65. EMBO J. 2015 Mar 12;34(6):739-47 - PubMed
  66. Nat Methods. 2010 Jan;7(1):56-9 - PubMed
  67. Int J Med Sci. 2014 Aug 22;11(11):1154-60 - PubMed
  68. Blood. 2011 Aug 18;118(7):1801-5 - PubMed
  69. Cell Rep. 2013 Jun 27;3(6):2088-99 - PubMed

Publication Types